Volume | 1,496,265 |
|
|||||
News | - | ||||||
Day High | 32.45 | Low High |
|||||
Day Low | 28.67 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
SpringWorks Therapeutics Inc | SWTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
30.14 | 28.67 | 32.45 | 31.90 | 30.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
23,361 | 1,496,265 | $ 31.22 | $ 46,718,222 | - | 18.00 - 34.16 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:44:01 | 12 | $ 32.99 | USD |
SpringWorks Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2B | 62.58M | - | 0 | -277.42M | -4.43 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
SpringWorks Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SWTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.75 | 33.506 | 20.1919 | 26.22 | 2,904,023 | 11.38 | 54.84% |
1 Month | 25.78 | 33.506 | 18.00 | 24.01 | 1,391,785 | 6.35 | 24.63% |
3 Months | 27.09 | 33.506 | 18.00 | 24.04 | 833,822 | 5.04 | 18.6% |
6 Months | 27.36 | 33.506 | 18.00 | 25.57 | 707,588 | 4.77 | 17.43% |
1 Year | 24.53 | 34.16 | 18.00 | 26.45 | 703,903 | 7.60 | 30.98% |
3 Years | 66.10 | 96.48 | 13.60 | 37.51 | 597,614 | -33.97 | -51.39% |
5 Years | 24.50 | 96.48 | 13.60 | 37.89 | 483,628 | 7.63 | 31.14% |
SpringWorks Therapeutics Description
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. |